Pharmacy Healthcare Solutions Inc. (PHSI) consults with pharmaceutical manufacturers, PBMs, retail pharmacy chains, and software companies on strategic business and marketing issues. Consulting projects across these market segments provide PHSI with the latest information on emerging trends as well as new products and services. Our consultants have extensive retail, mail service and managed care experience to create actionable recommendations for our clients’ challenging business issues.
PHSI Director of Business Development Fred Hamlin and PHSI Consultant Dave Schuetz will be attending the NCPDP Joint Technical Work Group Meetings February 1 to February 3, 2017 at the Hyatt Regency on the Riverwalk in San Antonio, TX. The Work Group Meetings provide a venue for NCPDP members and industry stakeholders to come together to Read More →
Starting in 2017, there will be 41 million beneficiaries enrolled in Medicare Part D plans. About 60% of these beneficiaries are enrolled in stand-alone prescription drug plans (PDPs), while the remaining 40% are in Medicare Advantage plans (MA-PDs). Although the total number of Part D beneficiaries has not substantially changed since 2016, the premiums and Read More →
PBMs and health plans have finalized their 2017 drug formularies, and payers have announced the products on this year’s highly anticipated formulary exclusion lists. While many of the drugs remain the same as the previous year, the increased presence of biosimilars and generic specialty drugs has caused some interesting changes for the exclusion lists. The Read More →
West Virginia is making it easier for physicians and pharmacists to determine a patient’s morphine equivalent doses when taking multiple opioids. By creating a calculator tool that will automatically pull records of all prescribed opioid medications for a patient from the Controlled Substance Monitoring Program (administered by the Board of Pharmacy) and calculate a dosage Read More →
Non-alcoholic steatohepatitis (NASH) is liver inflammation and damage caused by a buildup of fat. It is a more severe and progressive form of nonalcoholic fatty liver disease (NAFLD). While NAFLD has a relatively benign prognosis, NASH has a risk of progression to fibrosis, cirrhosis, and rarely liver cancer. About a quarter of patients with NAFLD Read More →
There are many different actions taking place to target opioid abuse and misuse. PHSI regularly posts about the DEA Drug Take Back Days. Prescription Drug Monitoring Programs enable healthcare providers to monitor patient use of opioids with the goal to reduce deaths due to opioid use. Changes are being made to make naloxone available without Read More →